AVBP Arrivent Biopharma, Inc.

Fundamentals / CIK 0001868279 / USD

Arrivent Biopharma, Inc. reported $417.1M in total assets and a net loss of $169.1M through December 31, 2025 from SEC EDGAR filings.

Audited annual (10-K / 20-F) and quarterly (10-Q) statements parsed directly from SEC EDGAR CompanyFacts. Open AVBP in the Convexity terminal for live prices, valuation multiples, transcripts, and insider flow.

Annual revenue and net income

3 fiscal years (2023 to 2025), reported in USD.

$0$0$0-$155.5MFY 2023 Net Income: -$69.33M2023FY 2024 Net Income: -$80.49M2024FY 2025 Net Income: -$166.3M2025

Financial statements and ratios

Reported in USD. Per-share figures and share counts are adjusted for stock splits from SEC filings.

Income Statement (Annual) · Reported in USD · Newest filing period first.

Income Statement Dec 31 Dec 31 Dec 31
Research & Development $153.4M $79.00M $64.88M
Total Operating Expenses $177.5M $94.31M $74.59M
Operating Income -$177.5M -$94.31M -$74.59M
EBITDA -$180.6M -- --
Net Income -$166.3M -$80.49M -$69.33M
Basic EPS -$4.32 -$2.56 -$32.38
Diluted EPS -$4.32 -$2.56 -$32.38
Basic Shares Outstanding 38.5M 31.5M 2.1M
Diluted Shares Outstanding 38.5M 31.5M 2.1M

Income Statement (Quarterly) · Reported in USD · Newest filing period first.

Income Statement 2026-09-30 2026-06-30 2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31
Revenue $5.00M -- -- -- -- -- -- --
Research & Development $38.90M $42.34M $37.62M $32.17M $32.17M $27.72M $61.29M $20.16M
Total Operating Expenses $48.38M $52.69M $46.11M $38.82M $38.32M $33.62M $66.77M $23.70M
Operating Income -$43.38M -$52.69M -$46.11M -$38.82M -$38.32M -$33.62M -$66.77M -$23.70M
EBITDA -$44.03M -$53.21M -$46.67M -- -- -- -- --
Net Income -$40.31M -$49.89M -$43.32M -$35.54M -$34.98M -$31.40M -$64.39M -$20.63M
Basic EPS -$0.81 -$1.05 -$0.96 -- -$0.83 -$0.90 -$1.90 --
Diluted EPS -$0.81 -$1.05 -$0.96 -- -$0.83 -$0.90 -$1.90 --
Basic Shares Outstanding 49.5M 47.6M 45.1M -- 41.9M 35.0M 33.9M --
Diluted Shares Outstanding 49.5M 47.6M 45.1M -- 41.9M 35.0M 33.9M --

Balance Sheet (Annual) · Reported in USD · Newest filing period first.

Balance Sheet Dec 31 Dec 31 Dec 31
Cash & Cash Equivalents $45.54M $74.29M $150.4M
Short-Term Investments $267.3M $144.6M --
Cash & Short-Term Investments $312.8M $218.9M $150.4M
Total Current Assets $332.9M $227.0M $160.0M
Long-Term Investments -- $47.68M --
Other Non-Current Assets $190K $126K $107K
Total Non-Current Assets $272K $47.96M $3.13M
Total Assets $333.2M $274.9M $163.1M
Accounts Payable $5.93M $3.78M $4.53M
Total Current Liabilities $25.95M $17.27M $11.62M
Total Non-Current Liabilities $0 $14K $177K
Total Liabilities $25.95M $17.29M $11.80M
Total Debt (incl. Leases) $14K $176K $317K
Common Stock $4.0K $3.0K --
Retained Earnings -$404.6M -$238.3M -$157.8M
Accumulated Other Comp. Income $14K -$211K --
Total Stockholders' Equity $307.2M $257.7M -$153.2M
Total Equity $307.2M $257.7M -$153.2M

Balance Sheet (Quarterly) · Reported in USD · Newest filing period first.

Balance Sheet 2026-09-30 2026-06-30 2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31
Cash & Cash Equivalents $113.6M $154.7M $62.10M $45.54M $112.7M $112.8M $49.87M $74.29M
Short-Term Investments $279.6M $218.4M $264.3M $267.3M $187.6M $122.9M $126.2M $144.6M
Cash & Short-Term Investments $393.2M $373.1M $326.4M $312.8M $300.3M $235.7M $176.1M $218.9M
Total Current Assets $416.6M $394.2M $348.7M $332.9M $321.2M $250.1M $185.8M $227.0M
Long-Term Investments -- -- -- -- $5.11M $18.79M $29.41M $47.68M
Other Non-Current Assets $134K $134K $156K $190K $180K $479K $176K $126K
Total Non-Current Assets $474K $545K $595K $272K $5.34M $19.36M $29.71M $47.96M
Total Assets $417.1M $394.7M $349.3M $333.2M $326.6M $269.5M $215.5M $274.9M
Accounts Payable $2.62M $2.22M $8.73M $5.93M $5.93M $4.06M $4.36M $3.78M
Total Current Liabilities -- $27.84M $25.00M $25.95M $21.56M $19.64M $12.95M $17.27M
Total Non-Current Liabilities -- $33K $320K $0 $0 $0 $0 $14K
Total Liabilities $23.61M $27.88M $25.32M $25.95M $21.56M $19.64M $12.95M $17.29M
Total Debt (incl. Leases) $256K $351K $419K $14K $56K $98K $138K $176K
Common Stock $5.0K $5.0K $5.0K $4.0K $4.0K $4.0K $4.0K $3.0K
Retained Earnings -$538.2M -$497.9M -$448.0M -$404.6M -$369.1M -$334.1M -$302.7M -$238.3M
Accumulated Other Comp. Income -$466K -$267K -$270K $14K $206K -$18K -$17K -$211K
Total Stockholders' Equity $393.5M $366.8M $324.0M $307.2M $305.0M $249.9M $202.5M $257.7M
Total Equity $393.5M $366.8M $324.0M $307.2M $305.0M $249.9M $202.5M $257.7M

Cash Flow Statement (Annual) · Reported in USD · Newest filing period first.

Cash Flow Statement Dec 31 Dec 31 Dec 31
Net Income -$166.3M -$80.49M -$69.33M
Depreciation & Amortization -$3.03M -- --
Stock-Based Compensation $12.52M $3.21M $895K
Change in Payables $2.14M -$751K $1.38M
Operating Cash Flow -$160.6M -$70.21M -$55.84M
Purchases of Investments -$272.9M -$194.2M --
Sales & Maturities of Investments $201.7M $1.70M --
Investing Cash Flow -$71.23M -$192.5M --
Common Stock Issued $202.6M $185.9M --
Financing Cash Flow $203.1M $186.6M $42.86M
Net Change in Cash -$28.75M -$76.10M -$12.98M

Cash Flow Statement (Quarterly) · Reported in USD · Newest filing period first.

Cash Flow Statement 2026-09-30 2026-06-30 2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31
Net Income -$40.31M -$49.89M -$43.32M -$35.54M -$34.98M -$31.40M -$64.39M -$20.63M
Depreciation & Amortization -$653K -$515K -$559K -- -- -- -- --
Stock-Based Compensation $6.88M $6.67M $5.49M $3.22M $3.72M $3.31M $2.27M $952K
Change in Payables $400K -$6.51M $2.81M -$8.0K $1.87M -$302K $582K -$865K
Operating Cash Flow -$40.71M -$39.58M -$41.89M -$30.66M -$35.80M -$26.12M -$68.01M -$16.15M
Purchases of Investments -$126.2M -$13.99M -$64.38M -$151.2M -$90.37M -$21.57M -$9.82M --
Sales & Maturities of Investments $65.57M $60.06M $67.97M $79.98M $39.61M $35.48M $46.64M --
Investing Cash Flow -$60.65M $46.07M $3.58M -$71.20M -$50.76M $13.91M $36.82M --
Common Stock Issued $59.66M $85.23M $54.72M $34.66M $86.12M $75.34M $6.52M $0
Financing Cash Flow $60.26M $86.09M $54.87M $34.73M $86.47M $75.11M $6.76M $55K
Net Change in Cash -$41.10M $92.58M $16.56M -$67.13M -$93K $62.90M -$24.43M -$208.6M

Margins, returns, leverage, liquidity, and year-over-year growth computed directly from SEC EDGAR statement levels. Multi-year figures show cumulative per-share growth.

Ratios & Growth Dec 31 Dec 31 Dec 31
Return on Equity (ROE) -54.1% -31.2% --
Return on Assets (ROA) -49.9% -29.3% -42.5%
Current Ratio 12.83x 13.14x 13.76x
Quick Ratio 12.06x 12.67x 12.94x
Debt to Equity 0.00x 0.00x --

Quarterly margins, ROE, and ROA use trailing-twelve-month (TTM) flows summed across four contiguous quarters. Growth rates are true year-over-year comparisons against the same quarter a year earlier.

Ratios & Growth 2026-09-30 2026-06-30 2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31
Return on Equity (ROE) -43.0% -44.6% -44.8% -54.1% -49.6% -54.8% -62.9% -31.2%
Return on Assets (ROA) -40.5% -41.5% -41.6% -49.9% -46.4% -50.8% -59.1% -29.3%
Current Ratio -- 14.16x 13.95x 12.83x 14.90x 12.74x 14.34x 13.14x
Quick Ratio -- 13.40x 13.06x 12.06x 13.93x 12.00x 13.59x 12.67x
Debt to Equity 0.00x 0.00x 0.00x 0.00x 0.00x 0.00x 0.00x 0.00x
Source: SEC EDGAR CompanyFacts (CIK 0001868279) · from March 31, 2023 Data through September 30, 2026 · synced Nov 20, 2026, 05:34 UTC · Open in terminal